# To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder

> **NCT04917315** · PHASE3 · COMPLETED · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 210 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** JLP-2002 A mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04917315
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-21
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-08-18
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2022-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04917315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04917315, "To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04917315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*